Cargando…
A Cost Evaluation of the Georgia Stroke and Heart Attack Prevention Program
INTRODUCTION: Hypertension is a leading cause of stroke, coronary artery disease, heart attack, and heart and kidney failure in the United States, all of which contribute to the rising costs of health care. The Georgia Stroke and Heart Attack Prevention Program is an education and direct service pro...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1500947/ https://www.ncbi.nlm.nih.gov/pubmed/16356365 |
_version_ | 1782128379601879040 |
---|---|
author | Rein, David B Orenstein, Diane Constantine, Roberta T Chen, Hong Jones, Patricia Brownstein, J. Nell Farris, Rosanne |
author_facet | Rein, David B Orenstein, Diane Constantine, Roberta T Chen, Hong Jones, Patricia Brownstein, J. Nell Farris, Rosanne |
author_sort | Rein, David B |
collection | PubMed |
description | INTRODUCTION: Hypertension is a leading cause of stroke, coronary artery disease, heart attack, and heart and kidney failure in the United States, all of which contribute to the rising costs of health care. The Georgia Stroke and Heart Attack Prevention Program is an education and direct service program for low-income patients with hypertension. This project evaluated the cost-effectiveness of the program compared with the following two alternative scenarios: no treatment for high blood pressure and the typical hypertension treatment received in the private sector nationwide (usual care). METHODS: We estimated the preventive treatment costs and number of adverse health events averted (hemorrhagic and ischemic stroke, heart disease, and kidney failure) associated with the Georgia Stroke and Heart Attack Prevention Program in two Georgia health districts. We used program cost and service usage data obtained from the Georgia Department of Human Resources and probabilities and costs of expected adverse events published in peer-reviewed sources. We compared program costs and number of expected adverse health events averted with those expected from 1) no preventive care and 2) usual care for high blood pressure. RESULTS: The Georgia Stroke and Heart Attack Prevention Program was less costly and resulted in better health outcomes than either no preventive care or usual care. Compared with no preventive care in the two districts, the program was estimated to result in 54% fewer expected adverse events; compared with usual care, the program was estimated to result in 46% fewer expected adverse events. Combining the costs of preventive treatment with the costs of expected adverse events, the Georgia Stroke and Heart Attack Prevention Program cost an average of $486 per patient annually, compared with average annual costs of $534 for no care and $624 for usual care. CONCLUSION: Maintaining a publicly financed stroke and heart attack prevention program is more cost-effective and results in greater health benefits than other plausible scenarios. Because the benefits of this program accrue to both the state and federal governments through reduced Medicaid and indigent care expenditures, both the state and federal governments have a financial incentive to support the program. |
format | Text |
id | pubmed-1500947 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | Centers for Disease Control and Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-15009472006-07-31 A Cost Evaluation of the Georgia Stroke and Heart Attack Prevention Program Rein, David B Orenstein, Diane Constantine, Roberta T Chen, Hong Jones, Patricia Brownstein, J. Nell Farris, Rosanne Prev Chronic Dis Original Research INTRODUCTION: Hypertension is a leading cause of stroke, coronary artery disease, heart attack, and heart and kidney failure in the United States, all of which contribute to the rising costs of health care. The Georgia Stroke and Heart Attack Prevention Program is an education and direct service program for low-income patients with hypertension. This project evaluated the cost-effectiveness of the program compared with the following two alternative scenarios: no treatment for high blood pressure and the typical hypertension treatment received in the private sector nationwide (usual care). METHODS: We estimated the preventive treatment costs and number of adverse health events averted (hemorrhagic and ischemic stroke, heart disease, and kidney failure) associated with the Georgia Stroke and Heart Attack Prevention Program in two Georgia health districts. We used program cost and service usage data obtained from the Georgia Department of Human Resources and probabilities and costs of expected adverse events published in peer-reviewed sources. We compared program costs and number of expected adverse health events averted with those expected from 1) no preventive care and 2) usual care for high blood pressure. RESULTS: The Georgia Stroke and Heart Attack Prevention Program was less costly and resulted in better health outcomes than either no preventive care or usual care. Compared with no preventive care in the two districts, the program was estimated to result in 54% fewer expected adverse events; compared with usual care, the program was estimated to result in 46% fewer expected adverse events. Combining the costs of preventive treatment with the costs of expected adverse events, the Georgia Stroke and Heart Attack Prevention Program cost an average of $486 per patient annually, compared with average annual costs of $534 for no care and $624 for usual care. CONCLUSION: Maintaining a publicly financed stroke and heart attack prevention program is more cost-effective and results in greater health benefits than other plausible scenarios. Because the benefits of this program accrue to both the state and federal governments through reduced Medicaid and indigent care expenditures, both the state and federal governments have a financial incentive to support the program. Centers for Disease Control and Prevention 2005-12-15 /pmc/articles/PMC1500947/ /pubmed/16356365 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited. |
spellingShingle | Original Research Rein, David B Orenstein, Diane Constantine, Roberta T Chen, Hong Jones, Patricia Brownstein, J. Nell Farris, Rosanne A Cost Evaluation of the Georgia Stroke and Heart Attack Prevention Program |
title | A Cost Evaluation of the Georgia Stroke and Heart Attack Prevention Program |
title_full | A Cost Evaluation of the Georgia Stroke and Heart Attack Prevention Program |
title_fullStr | A Cost Evaluation of the Georgia Stroke and Heart Attack Prevention Program |
title_full_unstemmed | A Cost Evaluation of the Georgia Stroke and Heart Attack Prevention Program |
title_short | A Cost Evaluation of the Georgia Stroke and Heart Attack Prevention Program |
title_sort | cost evaluation of the georgia stroke and heart attack prevention program |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1500947/ https://www.ncbi.nlm.nih.gov/pubmed/16356365 |
work_keys_str_mv | AT reindavidb acostevaluationofthegeorgiastrokeandheartattackpreventionprogram AT orensteindiane acostevaluationofthegeorgiastrokeandheartattackpreventionprogram AT constantinerobertat acostevaluationofthegeorgiastrokeandheartattackpreventionprogram AT chenhong acostevaluationofthegeorgiastrokeandheartattackpreventionprogram AT jonespatricia acostevaluationofthegeorgiastrokeandheartattackpreventionprogram AT brownsteinjnell acostevaluationofthegeorgiastrokeandheartattackpreventionprogram AT farrisrosanne acostevaluationofthegeorgiastrokeandheartattackpreventionprogram AT reindavidb costevaluationofthegeorgiastrokeandheartattackpreventionprogram AT orensteindiane costevaluationofthegeorgiastrokeandheartattackpreventionprogram AT constantinerobertat costevaluationofthegeorgiastrokeandheartattackpreventionprogram AT chenhong costevaluationofthegeorgiastrokeandheartattackpreventionprogram AT jonespatricia costevaluationofthegeorgiastrokeandheartattackpreventionprogram AT brownsteinjnell costevaluationofthegeorgiastrokeandheartattackpreventionprogram AT farrisrosanne costevaluationofthegeorgiastrokeandheartattackpreventionprogram |